Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

AGM Statement

8 Jun 2023 07:00

RNS Number : 0229C
Sopheon PLC
08 June 2023
 

SOPHEON PLC

 

("Sopheon" or the "Company")

 

AGM Statement

 

Sopheon plc, the InnovationOps software company, holds its Annual General Meeting ("AGM") today. The Board takes this opportunity to give shareholders the following update and review of the business.

 

2022 in review

 

Sopheon exited 2022 with two successful acquisitions and grew from a single product company to a family of four products, tripling Sopheon's addressable market to almost $3 billion. Sopheon's combined family of InnovationOps solutions offer a compelling and unique value proposition for companies: automate and provide a single source of truth to eliminate the innovation stalls, stumbles and failures that are completely avoidable in even the most chaotic of times. Each of our offerings are focused on specific innovation tasks that, when brought together with the people and processes across the organization, make InnovationOps a reality.

 

Our financial performance in 2022 illustrates the initial success of our efforts. ARR1 increased 17.4% to $24.3m (2022) compared to $20.7m (2021). Top line revenue rose to $36.8m compared to $34.4m in 2021. At constant currency, revenue would have exceeded $38m, representing 10% organic growth. Total contract value (TCV) of all sales closed in the year exceeded $30m up 35% year over year - with the exceptional outperformance attributable to signing the largest single deal in our history with the US Navy. Adjusted EBITDA2 improved by almost 12%, rising to $6.9m (2022: $6.2m) while taking a $1.6m write down in respect of technology investments superseded by the acquisitions.

 

2023 update and outlook

 

Following the impressive conclusion to 2022, in the first part of the current year we have maintained our drive on embedding our execution priorities as outlined in last year's annual report:

 

• Focus on SaaS/cloud sales

• Broadening our product offerings

• Introducing new pricing models

• Embed new leadership structures

• Continued customer centricity

 

These efforts have been accompanied by continued commercial progress. Since the start of the year, we have closed five new customer wins for Accolade, all SaaS, alongside several extension orders from existing customers. ARR has risen 18% to $25.7m compared to $21.7m a year ago, and year-to-date gross retention has held above 99%. Full year revenue visibility3 for recognizable 2023 revenue is currently at $31m, compared to $28m at this time last year. Management's confidence in our expected full year outturn is underpinned by a sales pipeline that includes major extensions with existing customers, alongside new prospects. Net cash at the end of May stood over $22m.

 

Sopheon has an incredible team of employees, our SaaS solution revenue continues to grow, and the balance sheet remains very strong to fuel additional acquisition and investment. The recent appointment of Barney Kent, former COO of Ideagen plc, as a non-executive Director underlines our commitment to both organic growth and M&A activities.

 

Sopheon's Chairman Andy Michuda said: "As I stated previously, we are now working to deliver rising velocity to our business, with an ambition to double run-rate revenue every four years alongside world class margin and retention metrics. In the early part of 2023, we have been very focused on further refining the three new products introduced in 2022 and are exploring further M&A opportunities. In parallel, both major new account wins and client expansion sales have delivered a further boost to visibility; and we remain busy with a number of sales opportunities as we approach the traditionally stronger second half of the year."

 

 

For further information contact:

Andy Michuda (Chairman)Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / George Dollemore (Corporate Finance)Alice Lane / Sunila de Silva (ECM)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

About Sopheon. Sopheon (LSE: SPE) empowers organizations to change the world while achieving exceptional long-term revenue growth and profitability. By operationalizing the entire innovation life cycle, Accolade® and Acclaim™ software and expertise enable innovation, product and project professionals to accomplish the full range of InnovationOps tasks to drive innovation at scale. Sopheon's industry leadership was highlighted in the comprehensive MarketsandMarkets™ report on the Innovation Management market, in which Sopheon was listed in the "Stars" category, the highest recognition. Sopheon's solutions have been implemented by hundreds of blue-chip customers with over 137,000 users in 50 countries. Sopheon is listed on the AIM Market of the London Stock Exchange. For more information, please visit www.sopheon.com.  

 

1 ARR is the annual value of all ongoing contracts for SaaS, hosting and maintenance in force at the measurement date including pending renewals and starts, including those which are contracted but conditional on acceptance decisions scheduled later in the year, but excluding confirmed terminations.

 

2Adjusted EBITDA is defined and reconciled in Note 5 of Sopheon's 2022 annual report which is available from the investor section of www.sopheon.com.

 

3 Revenue visibility comprises revenue expected from (i) closed license orders, including those which are contracted but conditional on acceptance decisions scheduled later in the year; (ii) contracted services business delivered or expected to be delivered in the year; and (iii) recurring maintenance, hosting, SaaS and rental streams. The visibility calculation does not include revenues from new sales opportunities expected to close during the remainder of the year.

 

Sopheon®, Accolade® and Acclaim™ are trademarks of Sopheon plc. All other trademarks are the property of their respective owners.

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (as amended) ("UK MAR").

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMFFFVIRAIDIIV
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.